Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress‐apoptosis gene expression in PBMCs of women with PCOS
July 2024
in “
Journal of Cellular and Molecular Medicine
”
TLDR Astaxanthin may reduce inflammation in women with PCOS, but doesn't significantly improve symptoms.
This randomized, double-blind clinical trial examined the effects of astaxanthin (ASX) supplementation on inflammatory markers and gene expression related to ER stress-apoptosis in 56 women with polycystic ovary syndrome (PCOS). Over 8 weeks, ASX significantly reduced inflammatory cytokines IL-18, IL-6, and TNF-α, but had no significant impact on CRP levels, BMI, hirsutism, hair loss, or menstrual cycle regularity. The study suggests ASX may help reduce inflammation and cellular stress in PCOS, though improvements in clinical symptoms were not statistically significant, indicating the need for further research with larger sample sizes and longer durations.